Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
An amendment to this paper has been published and can be accessed via the original article.
Main Authors: | Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | https://doi.org/10.1186/s13045-020-01023-9 |
Similar Items
-
Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01) -
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01) -
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
by: Patrick K. Reville, et al.
Published: (2021-03-01) -
Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01) -
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)